Key Stats for Pfizer Stock
- Past week’s performance: -1.9%
- 52-week range: $22 to $29
- Valuation model target price: $30
- Implied upside: 13.2% over 2.7 years
Value your favorite stocks like Pfizer with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Pfizer (PFE) stock ended the week near $27 as investors weighed a high dividend yield against weak growth expectations. The company declared a $0.43 second-quarter dividend, payable June 12 to shareholders of record on May 8. That matters because income remains one of the clearest reasons investors own Pfizer while the business works through post-COVID revenue declines.
PFE also got attention from new product and pipeline updates. Reuters reported that Pfizer’s GLP-1 weight-loss drug Xianweiying became available for pre-order in China, priced at 489 yuan per injector pen. GLP-1 drugs are used for diabetes and weight management, and this gives Pfizer exposure to a fast-growing category dominated by Novo Nordisk and Eli Lilly.
Pfizer’s oncology pipeline also remains central to the story. PFE announced positive Phase 2 results for atirmociclib in second-line metastatic breast cancer. Atirmociclib is a next-generation CDK4 inhibitor, a type of cancer drug designed to slow tumor cell growth.
The tone is cautious but improving. Pfizer still expects 2026 revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00. Investors are waiting to see whether Q1 earnings on May 5 show enough pipeline and cost progress to support the stock going forward.
See analysts’ growth forecasts and price targets for Pfizer (It’s free) >>>
Is Pfizer Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): -1.6%
- Operating Margins: 35.1%
- Exit P/E Multiple: 9.1x
Based on these inputs, the model estimates a target price of $30, implying 13.2% total upside from the current share price and a 4.7% annualized return over the next 2.7 years.
That return profile looks modest. Pfizer trades at 9.1x next-twelve-month earnings, below its 10-year historical P/E of 11.9x. The discount reflects declining revenue, patent risk, and uncertainty around replacing lost COVID-related sales.
The business is still highly profitable. LTM revenue is $62.6 billion, gross margin is 75.8%, and EBIT margin is 30.6%. Those margins show Pfizer still has strong pharmaceutical economics, even while growth remains under pressure.
The dividend is a major part of the valuation case. Pfizer’s dividend yield is 6.5%, but its payout ratio is 125.7%. That means dividend coverage depends on earnings recovery, cash flow, and cost reductions.
What’s Driving PFE Stock Going Forward?
The next catalyst is Q1 earnings on May 5. Investors will want to see whether Pfizer is stabilizing after the COVID revenue reset. The key question is not just whether revenue meets guidance, but whether management can show that non-COVID products are becoming the main growth engine again.
Cost savings will also matter. Pfizer has been cutting expenses to protect margins while revenue growth remains weak. If those savings show up in operating profit, the stock could get support even without major revenue acceleration.
Pipeline execution is the biggest long-term driver. Pfizer needs new products in oncology, obesity, vaccines, and immunology to offset weaker COVID demand and future patent losses. Positive trial updates would matter because they give investors a clearer path to replacing lost revenue.
Oncology is especially important. Pfizer’s atirmociclib breast cancer data and Padcev-Keytruda bladder cancer review could help strengthen its cancer portfolio. If these programs move forward, investors may assign more value to Pfizer’s pipeline instead of treating the company mainly as a low-growth dividend stock.
The China GLP-1 launch is another area to watch. Pfizer’s Xianweiying gives the company exposure to the weight-loss market, which has become one of the most important growth areas in pharma. The opportunity is meaningful, but Pfizer must prove it can compete in a market led by established obesity drug leaders.
Dividend coverage could also drive sentiment. Pfizer’s 6.5% yield is attractive, but the 125.7% payout ratio raises questions about sustainability. Strong free cash flow and better earnings visibility would help reassure income investors.
Balance sheet discipline matters too. Pfizer has about $54.1 billion in LTM net debt and a net debt to EBITDA of 2.03x. The stock needs evidence that management can fund the dividend, reduce debt, and still invest in the pipeline.
Overall, Pfizer’s stock will likely move on proof of recovery rather than one headline. Investors need to see stable base business sales, stronger margins, pipeline progress, and reliable cash flow. If those pieces improve together, the market may become more willing to re-rate Pfizer going forward.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Pfizer?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up PFE, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track PFE alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Pfizer stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
